Little Bertis B, Snell Laura M, Van Beveren Toosje T, Crowell R Becca, Trayler Stacey, Johnston Walter L
Tarleton State University, Stephenville, Texas 76402-0010, USA.
Am J Perinatol. 2003 Jul;20(5):255-62. doi: 10.1055/s-2003-42336.
The objective of this study is to analyze the effects of residential substance abuse treatment on pregnancy outcome among gravidas in a gender-specific program. All clients (cases) who entered a residential substance abuse program for pregnant and postpartum women were eligible for inclusion in the study (n=95). Only those who were in treatment at the time of delivery were included in the present analysis (n=57). Two comparison groups were used: (1) substance abusers who received no treatment during pregnancy (positive control group) and (2) pregnant women who were not substance abusers (negative control group). Cases were matched to controls on ethnicity (negative and positive controls) and drug of choice (positive controls only). Medical records were reviewed and abstracted for cases and controls. The primary drug of choice was cocaine for 56% of clients in the study, heroin 15.8%, and alcohol 10.8%. Average length of time in treatment before delivery was 11.7 weeks. The frequency of pregnancy complications allowing treatment and position controls was significantly higher than the negative control group (p<0.0001). The frequency of perinatal infant complications was increased among treatment group infants (p<0.0001). Two infants in the treatment group were positive for a substance of abuse at birth. In the treatment versus positive control group, mean birth weight (BW) was 3227 versus 2800 g (p<0.01), estimated gestational age (EGA) was 38.9 versus 39 weeks, average head circumference (FOC) was 33.8 versus 32.5 cm (p<0.05), and mean birth length (BLT) was 48.7 cm versus 46.9 (p<0.05). No significant differences were found between treatment and negative control groups. Maternal syphilis was increased in frequency in the positive control group compared with the negative control group (p<0.07). Thirty-percent of mothers had sexually transmitted diseases (STDs) for which infants were at risk and treated prophylactically; no infant in the treatment group contracted a vertically transmitted STD. For every 10 weeks in treatment, BW was increased 340 g, EGA 1 week, FOC 0.8 cm, and BLT 1.8 cm. Thus, substance abuse treatment for pregnant women in the program increased fetal growth, which significantly decreased the risk for poor neonatal outcomes. Importantly, maternal and infant perinatal complications in the treatment group were increased in frequency compared with the two control groups. This may possibly have occurred because healthcare providers were not blinded to maternal treatment status.
本研究的目的是分析在一个针对性别的项目中,住院药物滥用治疗对孕妇妊娠结局的影响。所有进入针对孕妇和产后妇女的住院药物滥用项目的客户(病例)均符合纳入本研究的条件(n = 95)。仅将分娩时正在接受治疗的那些人纳入本分析(n = 57)。使用了两个对照组:(1)孕期未接受治疗的药物滥用者(阳性对照组)和(2)非药物滥用的孕妇(阴性对照组)。病例在种族(阴性和阳性对照组)和首选药物(仅阳性对照组)方面与对照组进行匹配。对病例和对照组的病历进行了审查和摘要。本研究中56%的客户首选药物为可卡因,15.8%为海洛因,10.8%为酒精。分娩前平均治疗时间为11.7周。允许治疗的妊娠并发症发生率和位置对照组显著高于阴性对照组(p<0.0001)。治疗组婴儿的围产期并发症发生率有所增加(p<0.0001)。治疗组中有两名婴儿出生时对一种滥用物质检测呈阳性。在治疗组与阳性对照组中,平均出生体重(BW)分别为3227克和2800克(p<0.01),估计孕周(EGA)分别为38.9周和39周,平均头围(FOC)分别为33.8厘米和32.5厘米(p<0.05),平均出生身长(BLT)分别为48.7厘米和46.9厘米(p<0.05)。治疗组与阴性对照组之间未发现显著差异。与阴性对照组相比,阳性对照组中孕妇梅毒的发生率有所增加(p<0.07)。30%的母亲患有婴儿有感染风险并接受了预防性治疗的性传播疾病(STD);治疗组中没有婴儿感染垂直传播的STD。每接受10周治疗,出生体重增加340克,孕周增加1周,头围增加S0.8厘米,出生身长增加1.8厘米。因此,该项目中对孕妇的药物滥用治疗促进了胎儿生长,显著降低了不良新生儿结局的风险。重要的是,与两个对照组相比,治疗组中母婴围产期并发症的发生率有所增加。这可能是因为医疗保健提供者未对产妇的治疗状态设盲。